Report cover image

Global Biliary Tumor Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 191 Pages
SKU # APRC20561687

Description

Summary

According to APO Research, The global Biliary Tumor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Biliary Tumor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biliary Tumor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biliary Tumor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biliary Tumor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Biliary Tumor include Novartis, GlaxoSmithKline, Southwest Oncology Group, NuCana and NeoGenomics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biliary Tumor, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biliary Tumor, also provides the revenue of main regions and countries. Of the upcoming market potential for Biliary Tumor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biliary Tumor revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biliary Tumor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Biliary Tumor revenue, projected growth trends, production technology, application and end-user industry.

Biliary Tumor Segment by Company

Novartis
GlaxoSmithKline
Southwest Oncology Group
NuCana
NeoGenomics
Biliary Tumor Segment by Type

Mecine
Surgery
Other
Biliary Tumor Segment by Application

Hospitals
Clinics
Other
Biliary Tumor Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biliary Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biliary Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biliary Tumor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Biliary Tumor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Biliary Tumor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biliary Tumor revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Biliary Tumor Market by Type
1.2.1 Global Biliary Tumor Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Mecine
1.2.3 Surgery
1.2.4 Other
1.3 Biliary Tumor Market by Application
1.3.1 Global Biliary Tumor Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biliary Tumor Market Dynamics
2.1 Biliary Tumor Industry Trends
2.2 Biliary Tumor Industry Drivers
2.3 Biliary Tumor Industry Opportunities and Challenges
2.4 Biliary Tumor Industry Restraints
3 Global Growth Perspective
3.1 Global Biliary Tumor Market Perspective (2020-2031)
3.2 Global Biliary Tumor Growth Trends by Region
3.2.1 Global Biliary Tumor Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Biliary Tumor Market Size by Region (2020-2025)
3.2.3 Global Biliary Tumor Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Biliary Tumor Revenue by Players
4.1.1 Global Biliary Tumor Revenue by Players (2020-2025)
4.1.2 Global Biliary Tumor Revenue Market Share by Players (2020-2025)
4.1.3 Global Biliary Tumor Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Biliary Tumor Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Biliary Tumor Key Players Headquarters & Area Served
4.4 Global Biliary Tumor Players, Product Type & Application
4.5 Global Biliary Tumor Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Biliary Tumor Market CR5 and HHI
4.6.3 2024 Biliary Tumor Tier 1, Tier 2, and Tier 3
5 Biliary Tumor Market Size by Type
5.1 Global Biliary Tumor Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Biliary Tumor Revenue by Type (2020-2031)
5.3 Global Biliary Tumor Revenue Market Share by Type (2020-2031)
6 Biliary Tumor Market Size by Application
6.1 Global Biliary Tumor Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Biliary Tumor Revenue by Application (2020-2031)
6.3 Global Biliary Tumor Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Comapny Information
7.1.2 Novartis Business Overview
7.1.3 Novartis Biliary Tumor Revenue and Gross Margin (2020-2025)
7.1.4 Novartis Biliary Tumor Product Portfolio
7.1.5 Novartis Recent Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Comapny Information
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Biliary Tumor Revenue and Gross Margin (2020-2025)
7.2.4 GlaxoSmithKline Biliary Tumor Product Portfolio
7.2.5 GlaxoSmithKline Recent Developments
7.3 Southwest Oncology Group
7.3.1 Southwest Oncology Group Comapny Information
7.3.2 Southwest Oncology Group Business Overview
7.3.3 Southwest Oncology Group Biliary Tumor Revenue and Gross Margin (2020-2025)
7.3.4 Southwest Oncology Group Biliary Tumor Product Portfolio
7.3.5 Southwest Oncology Group Recent Developments
7.4 NuCana
7.4.1 NuCana Comapny Information
7.4.2 NuCana Business Overview
7.4.3 NuCana Biliary Tumor Revenue and Gross Margin (2020-2025)
7.4.4 NuCana Biliary Tumor Product Portfolio
7.4.5 NuCana Recent Developments
7.5 NeoGenomics
7.5.1 NeoGenomics Comapny Information
7.5.2 NeoGenomics Business Overview
7.5.3 NeoGenomics Biliary Tumor Revenue and Gross Margin (2020-2025)
7.5.4 NeoGenomics Biliary Tumor Product Portfolio
7.5.5 NeoGenomics Recent Developments
8 North America
8.1 North America Biliary Tumor Revenue (2020-2031)
8.2 North America Biliary Tumor Revenue by Type (2020-2031)
8.2.1 North America Biliary Tumor Revenue by Type (2020-2025)
8.2.2 North America Biliary Tumor Revenue by Type (2026-2031)
8.3 North America Biliary Tumor Revenue Share by Type (2020-2031)
8.4 North America Biliary Tumor Revenue by Application (2020-2031)
8.4.1 North America Biliary Tumor Revenue by Application (2020-2025)
8.4.2 North America Biliary Tumor Revenue by Application (2026-2031)
8.5 North America Biliary Tumor Revenue Share by Application (2020-2031)
8.6 North America Biliary Tumor Revenue by Country
8.6.1 North America Biliary Tumor Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Biliary Tumor Revenue by Country (2020-2025)
8.6.3 North America Biliary Tumor Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Biliary Tumor Revenue (2020-2031)
9.2 Europe Biliary Tumor Revenue by Type (2020-2031)
9.2.1 Europe Biliary Tumor Revenue by Type (2020-2025)
9.2.2 Europe Biliary Tumor Revenue by Type (2026-2031)
9.3 Europe Biliary Tumor Revenue Share by Type (2020-2031)
9.4 Europe Biliary Tumor Revenue by Application (2020-2031)
9.4.1 Europe Biliary Tumor Revenue by Application (2020-2025)
9.4.2 Europe Biliary Tumor Revenue by Application (2026-2031)
9.5 Europe Biliary Tumor Revenue Share by Application (2020-2031)
9.6 Europe Biliary Tumor Revenue by Country
9.6.1 Europe Biliary Tumor Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Biliary Tumor Revenue by Country (2020-2025)
9.6.3 Europe Biliary Tumor Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Biliary Tumor Revenue (2020-2031)
10.2 China Biliary Tumor Revenue by Type (2020-2031)
10.2.1 China Biliary Tumor Revenue by Type (2020-2025)
10.2.2 China Biliary Tumor Revenue by Type (2026-2031)
10.3 China Biliary Tumor Revenue Share by Type (2020-2031)
10.4 China Biliary Tumor Revenue by Application (2020-2031)
10.4.1 China Biliary Tumor Revenue by Application (2020-2025)
10.4.2 China Biliary Tumor Revenue by Application (2026-2031)
10.5 China Biliary Tumor Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Biliary Tumor Revenue (2020-2031)
11.2 Asia Biliary Tumor Revenue by Type (2020-2031)
11.2.1 Asia Biliary Tumor Revenue by Type (2020-2025)
11.2.2 Asia Biliary Tumor Revenue by Type (2026-2031)
11.3 Asia Biliary Tumor Revenue Share by Type (2020-2031)
11.4 Asia Biliary Tumor Revenue by Application (2020-2031)
11.4.1 Asia Biliary Tumor Revenue by Application (2020-2025)
11.4.2 Asia Biliary Tumor Revenue by Application (2026-2031)
11.5 Asia Biliary Tumor Revenue Share by Application (2020-2031)
11.6 Asia Biliary Tumor Revenue by Country
11.6.1 Asia Biliary Tumor Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Biliary Tumor Revenue by Country (2020-2025)
11.6.3 Asia Biliary Tumor Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Biliary Tumor Revenue (2020-2031)
12.2 SAMEA Biliary Tumor Revenue by Type (2020-2031)
12.2.1 SAMEA Biliary Tumor Revenue by Type (2020-2025)
12.2.2 SAMEA Biliary Tumor Revenue by Type (2026-2031)
12.3 SAMEA Biliary Tumor Revenue Share by Type (2020-2031)
12.4 SAMEA Biliary Tumor Revenue by Application (2020-2031)
12.4.1 SAMEA Biliary Tumor Revenue by Application (2020-2025)
12.4.2 SAMEA Biliary Tumor Revenue by Application (2026-2031)
12.5 SAMEA Biliary Tumor Revenue Share by Application (2020-2031)
12.6 SAMEA Biliary Tumor Revenue by Country
12.6.1 SAMEA Biliary Tumor Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Biliary Tumor Revenue by Country (2020-2025)
12.6.3 SAMEA Biliary Tumor Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.